NanoString Technologies, Inc. develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers nCounter based reagents that allow users to design customized assays; Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics; and Hyb & Seq technologies. It has collaboration with Lam Research Corporation for the research and development of Hyb & Seq technologies; Celgene Corporation for developing LymphMark, an in vitro diagnostic for the treatment of diffuse large B-cell lymphoma; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer. NanoString Technologies, Inc. was founded in 2003 and is headquartered in Seattle, Washington. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
BEECHEM JOSEPH M | SVP, Research & Development | Mar 15 | Sale | 27.81 | 2,436 | 67,740 | 85,372 | Mar 16 04:40 PM | Bailey K Thomas | Chief Financial Officer | Mar 15 | Sale | 27.81 | 2,110 | 58,675 | 19,372 | Mar 16 04:40 PM | GRAY R BRADLEY | President and CEO | Mar 15 | Sale | 27.81 | 8,625 | 239,844 | 202,298 | Mar 16 04:41 PM | GRAY R BRADLEY | President and CEO | Mar 14 | Option Exercise | 0.00 | 21,994 | 0 | 210,923 | Mar 16 04:41 PM | Bailey K Thomas | Chief Financial Officer | Mar 14 | Option Exercise | 0.00 | 5,377 | 0 | 21,482 | Mar 16 04:40 PM | BEECHEM JOSEPH M | SVP, Research & Development | Mar 14 | Option Exercise | 0.00 | 5,377 | 0 | 87,808 | Mar 16 04:40 PM | Bailey K Thomas | Chief Financial Officer | Mar 10 | Sale | 33.81 | 5,000 | 169,050 | 16,105 | Mar 11 08:04 PM | GEORGE JANET | Director | Mar 08 | Option Exercise | 0.00 | 1,676 | 0 | 1,676 | Mar 09 05:26 PM | ROLLISON DANA E. | Director | Mar 08 | Option Exercise | 0.00 | 1,676 | 0 | 1,676 | Mar 09 05:26 PM | Bailey K Thomas | Chief Financial Officer | Mar 08 | Sale | 33.06 | 3,058 | 101,110 | 21,105 | Mar 09 05:24 PM | GRAY R BRADLEY | President and CEO | Mar 08 | Sale | 33.06 | 9,667 | 319,630 | 188,929 | Mar 09 05:25 PM | BEECHEM JOSEPH M | SVP, Research & Development | Mar 08 | Sale | 33.06 | 2,968 | 98,134 | 82,431 | Mar 09 05:25 PM | BEECHEM JOSEPH M | SVP, Research & Development | Mar 07 | Option Exercise | 0.00 | 6,505 | 0 | 85,399 | Mar 09 05:25 PM | GRAY R BRADLEY | President and CEO | Mar 07 | Option Exercise | 0.00 | 24,526 | 0 | 198,596 | Mar 09 05:25 PM | Bailey K Thomas | Chief Financial Officer | Mar 07 | Option Exercise | 0.00 | 7,753 | 0 | 24,163 | Mar 09 05:24 PM | Bailey K Thomas | Chief Financial Officer | Jan 27 | Option Exercise | 0.00 | 13,709 | 0 | 19,928 | Jan 31 09:48 PM | BEECHEM JOSEPH M | SVP, Research & Development | Jan 27 | Option Exercise | 0.00 | 13,709 | 0 | 85,218 | Jan 31 09:48 PM | GRAY R BRADLEY | President and CEO | Jan 27 | Option Exercise | 0.00 | 56,085 | 0 | 195,866 | Jan 31 09:49 PM | Bailey K Thomas | Chief Financial Officer | Nov 17 | Option Exercise | 11.85 | 7,843 | 92,932 | 7,843 | Nov 19 04:11 PM | Bailey K Thomas | Chief Financial Officer | Nov 17 | Sale | 46.74 | 7,843 | 366,580 | 0 | Nov 19 04:11 PM | GRAY R BRADLEY | President and CEO | Nov 10 | Option Exercise | 6.72 | 12,500 | 84,000 | 148,324 | Nov 12 04:27 PM | GRAY R BRADLEY | President and CEO | Nov 10 | Sale | 46.29 | 25,000 | 1,157,299 | 123,324 | Nov 12 04:27 PM | Malloy Kirk | Director | Sep 13 | Option Exercise | 19.33 | 3,000 | 57,990 | 9,510 | Sep 15 04:35 PM | Malloy Kirk | Director | Sep 13 | Sale | 59.37 | 3,000 | 178,110 | 6,510 | Sep 15 04:35 PM | GRAY R BRADLEY | President and CEO | Sep 08 | Option Exercise | 6.72 | 12,500 | 84,000 | 169,158 | Sep 10 04:38 PM | GRAY R BRADLEY | President and CEO | Sep 08 | Sale | 57.92 | 33,334 | 1,930,804 | 135,824 | Sep 10 04:38 PM | BEECHEM JOSEPH M | SVP, Research & Development | Sep 02 | Sale | 61.14 | 23,114 | 1,413,206 | 68,270 | Sep 03 05:13 PM | Bailey K Thomas | Chief Financial Officer | Aug 17 | Option Exercise | 11.85 | 7,845 | 92,963 | 7,845 | Aug 19 04:18 PM | Bailey K Thomas | Chief Financial Officer | Aug 17 | Sale | 51.98 | 7,845 | 407,776 | 0 | Aug 19 04:18 PM | Malloy Kirk | Director | Aug 16 | Option Exercise | 26.45 | 1,500 | 39,675 | 8,010 | Aug 18 05:09 PM | Malloy Kirk | Director | Aug 16 | Sale | 55.82 | 1,500 | 83,730 | 6,510 | Aug 18 05:09 PM | BROWN J. CHAD | SVP, Sales & Marketing | Jul 30 | Option Exercise | 17.82 | 11,106 | 197,920 | 11,106 | Aug 03 04:49 PM | BROWN J. CHAD | SVP, Sales & Marketing | Jul 30 | Sale | 62.09 | 11,106 | 689,598 | 0 | Aug 03 04:49 PM | Malloy Kirk | Director | Jul 13 | Option Exercise | 23.34 | 1,500 | 35,010 | 8,010 | Jul 15 04:38 PM | Malloy Kirk | Director | Jul 13 | Sale | 61.16 | 1,500 | 91,740 | 6,510 | Jul 15 04:38 PM | FINNEY ELISHA W | Director | Jun 16 | Sale | 58.70 | 2,760 | 162,012 | 4,650 | Jun 17 07:04 PM | Malloy Kirk | Director | Jun 14 | Option Exercise | 7.47 | 168 | 1,255 | 1,158 | Jun 15 04:34 PM | Malloy Kirk | Director | Jun 14 | Sale | 60.05 | 168 | 10,088 | 990 | Jun 15 04:34 PM | BEECHEM JOSEPH M | SVP, Research & Development | Jun 11 | Option Exercise | 6.74 | 142,967 | 963,592 | 223,002 | Jun 15 04:35 PM | BEECHEM JOSEPH M | SVP, Research & Development | Jun 11 | Sale | 58.94 | 131,827 | 7,770,339 | 91,175 | Jun 15 04:35 PM | Bailey K Thomas | Chief Financial Officer | May 18 | Option Exercise | 11.85 | 5,229 | 61,962 | 5,229 | May 20 04:24 PM | Bailey K Thomas | Chief Financial Officer | May 18 | Sale | 51.10 | 5,229 | 267,217 | 0 | May 20 04:24 PM |
|